Learnings & Misgivings

The Advinus Decade: Inside the Tata Group’s expensive drug discovery flameout

Born 2005. Died 2017. Several hundred crores poorer, the Tata Group has finally pulled the plug on its ambitious drug discovery venture. What went wrong?

landscape-411712_1280.jpg

A decade is a long enough time in any business, however risky its premise or exploratory its process, to prove whether it’ll return value to its investors or not. This was evident last month when the news broke that the Tata group was selling Advinus Therapeutics to Eurofins Scientific, a contract research and manufacturing company in Luxembourg. What seemed like a masterful strategy 10 years ago, to get into a new business of discovering drugs and licensing out to big pharma, ended up in a messy exit.

No one has…

To access this content, you must purchase Quarterly, or log in if you are a member.

Sign up to read this story
for free right away

Stories on The Ken are available only for its subscribers. This story is shared with you for free, just sign up to get instant access.

Have an account?

Related stories

More stories in /Business/Reportage & /Science

See all in BusinessReportage & Science

Sign up for free to read this story right now. Sign up for free

Sign up to read this story for free right away

Stories on The Ken are available only for its subscribers. This story is shared with you for free, just sign up to get instant access.

Why should I pay for reading your stories?

Lots of effort We go to lengths to put in time and resources required to get the most factual, honest stories out there.

Advertising independent Our primary allegiance will always be to our readers. We won't be swayed by our advertisers and investors.

We can't do all of this by giving away our journalism for free and selling our readers by the thousands to advertisers.

Get premium access